Human T cell leukemia virus type 1 (HTLV-1) is mainly transmitted vertically through breast milk. The rate of mother-to-child transmission (MTCT) through formula feeding, although significantly lower than through breastfeeding, is approximately 2.4%–3.6%, suggesting the possibility of alternative transmission routes. MTCT of HTLV-1 might occur through the uterus, birth canal, or placental tissues; the latter is known as transplacental transmission. Here, we found that HTLV-1 proviral DNA was present in the placental villous tissues of the fetuses of nearly half of pregnant carriers and in a small number of cord blood samples. An RNA ISH assay showed that HTLV-1–expressing cells were present in nearly all subjects with HTLV-1–positive placental villous tissues, and their frequency was significantly higher in subjects with HTLV-1–positive cord blood samples. Furthermore, placental villous trophoblasts expressed HTLV-1 receptors and showed increased susceptibility to HTLV-1 infection. In addition, HTLV-1–infected trophoblasts expressed high levels of viral antigens and promoted the de novo infection of target T cells in a humanized mouse model. In summary, during pregnancy of HTLV-1 carriers, HTLV-1 was highly expressed in placental villous tissues, and villous trophoblasts showed high HTLV-1 sensitivity, suggesting that MTCT of HTLV-1 occurs through the placenta.
Rationale: Amniotic fluid embolism (AFE) is a fatal obstetric condition that often rapidly leads to severe respiratory and circulatory failure. It is complicated by obstetric disseminated intravascular coagulation (DIC) with bleeding tendency; therefore, the introduction of venoarterial extracorporeal membrane oxygenation (VA-ECMO) is challenging. We report the case of a patient with AFE requiring massive blood transfusion, rescued using VA-ECMO without initial anticoagulation. Patient’s concerns: A 39-year-old pregnant patient was admitted with a complaint of abdominal pain. An emergency cesarean section was performed because a sudden decrease in fetal heart rate was detected in addition to DIC with hyperfibrinolysis. Intra- and post-operatively, the patient had a bleeding tendency and required massive blood transfusions. After surgery, the patient developed lethal respiratory and circulatory failure, and VA-ECMO was introduced. Diagnosis: Based on the course of the illness and imaging findings, the patient was diagnosed with AFE. Interventions: By controlling the bleeding tendency with a massive transfusion and tranexamic acid administration, using an antithrombotic ECMO circuit, and delaying the initiation of anticoagulation and anti-DIC medication until the bleeding tendency settled, the patient was managed safely on ECMO without complications. Outcomes: By day 5, both respiration and circulation were stable, and the patient was weaned off VA-ECMO. Mechanical ventilation was discontinued on day 6. Finally, she was discharged home without sequelae. Lessons: VA-ECMO may be effective to save the lives of patients who have AFE with lethal circulatory and respiratory failure. For safe management without bleeding complications, it is important to start VA-ECMO without initial anticoagulants and to administer anticoagulants and anti-DIC drugs after the bleeding tendency has resolved.
24 September 2025 in Journal of Obstetrics and Gynaecology Research
Introduction The incidence of invasive moles and choriocarcinoma after uterine evacuation differs between a complete hydatidiform mole (CHM) and a partial hydatidiform mole (PHM). Accurately distinguishing between these two types is important. This study aimed to investigate diagnostic differences in hydatidiform moles using p57kip2 immunohistochemistry and DNA genotyping analysis in trophoblastic tissue. Materials and methods Twenty-four patients who underwent uterine evacuation or total hysterectomy for suspected hydatidiform moles between 2013 and 2022 were included in this study. Pathologists performed p57kip2 immunohistochemistry in addition to hematoxylin and eosin staining. A DNA genotyping analysis was performed on hydatidiform villus tissue and blood samples from patients and their partners (if possible) to differentiate between CHM and PHM. Results Of the 16 CHM cases diagnosed histologically, one was diagnosed as decidua by DNA genotyping. Of the eight PHM cases diagnosed histologically because of positive p57kip2 immunohistochemistry, four were diagnosed as CHM by DNA genotyping, and two were diagnosed as decidua. The sensitivity, specificity, positive predictive value, and negative predictive value of the pathological diagnosis of the 21 cases, excluding the three cases diagnosed as decidua by DNA testing, were 100%, 33%, 71.4%, and 28.6%, respectively (P = 0.0183, Pearson’s chi-square test). Of the 24 cases, blood samples were obtained from the partners in 15 cases. Of the 15 cases, 12 were homodisomy and three were heterodisomy. Conclusions Hematoxylin and eosin staining and p57kip2 immunohistochemistry are useful tools for differentiating CHM from PHM, but combining them with DNA genotyping analysis leads to a more accurate and reliable diagnosis.